THE APEX TIMES
Eli Lilly Canada said Health Canada has issued a Notice of Compliance for Mounjaro (tirzepatide) with an indication aimed at lowering the risk of major cardiovascular events in adults living with type 2 diabetes.
Eli Lilly said Health Canada has issued a Notice of Compliance (NOC) for Mounjaro (tirzepatide) in an expanded use intended to reduce cardiovascular risk in adults with type 2 diabetes. The approval, announced by Eli Lilly Canada, marks a regulatory step that ties the drug’s benefits to cardiovascular outcomes, not only blood-sugar management or weight-related effects.
Mounjaro is described by the company as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) hormone receptor agonist. In plain terms, it is designed to activate two incretin-related pathways involved in insulin secretion and metabolic regulation. The company’s statement frames the new authorization around lowering the risk of major adverse cardiovascular events in the eligible adult type 2 diabetes population.
The filing language reported in the announcement centers on Health Canada’s issuance of the NOC, the formal Canadian regulatory approval status indicating that the product meets Health Canada’s requirements to be marketed for the specified indication(s). Eli Lilly Canada did not, in the reported post, provide granular details on the target patient profile beyond “adults with type 2 diabetes,” nor did it outline specific event components or threshold definitions that would qualify as “major adverse cardiovascular” outcomes.
The approval also indicates how diabetes drug labels are increasingly being shaped by cardiovascular data. For years, regulators have shown heightened interest in whether therapies meaningfully change the risk of heart attacks, strokes, or cardiovascular death in people with type 2 diabetes, a group known to carry elevated baseline cardiovascular risk. A cardiovascular-focused indication can broaden the set of clinical conversations in which a drug is considered.
For Eli Lilly, Mounjaro has been a central growth product, and a cardiovascular indication can affect prescribing patterns by positioning the medication as part of heart-risk management. While the announcement does not disclose additional label elements such as whether the indication is limited by comorbidities or by prior cardiovascular history, the existence of the NOC itself provides a new regulatory pathway for physicians to use the drug with cardiovascular risk reduction as an explicit therapeutic goal.
Industry-wide, cardiovascular outcome language is also closely watched because it can influence how payers and guideline committees interpret value. However, the company’s announcement, as reported, does not address reimbursement coverage, formulary timing, or how quickly the updated indication will translate into broader access in Canadian health plans.
Beyond the approval itself, Eli Lilly did not provide, in the reported material, details such as the specific clinical study or endpoint definitions Health Canada relied on for the cardiovascular claim. The post also did not mention whether the NOC is linked to any post-authorization commitments, additional monitoring requirements, or a timeline for updates to prescribing materials in Canada.
What to watch next is how Eli Lilly and its Canadian affiliate implement the label change in practice, including the timing of updated product monographs and marketing communications. It will also be important to see whether this cardiovascular indication is reflected in other major markets and whether future regulatory decisions elsewhere follow a similar pattern. Investors and clinicians alike will likely look for subsequent disclosures that clarify the eligible patient subgroup and the exact cardiovascular outcome measure used for the claim.
Investors moved quickly after early outlines connected United Launch Alliance’s work to the BE-4 engine family, which Blue Origin’s New Glenn is expected to use for a planned 2027 flight carrying AST SpaceMobile’s BlueBird satellites.
A report tied to Anthropic’s debut highlights a cash position large enough to dwarf the combined figures of Amazon and NVIDIA, while also pointing to a new exchange-traded fund built around companies described as “ANT-linked.”
A Yahoo Finance report highlights how Berkshire Hathaway’s roughly $10 billion investment in Alphabet appears to be losing value, with Bill Ackman commenting that the timing and pricing were unexpected even as he noted the stake was bought at a perceived discount.
The company said it has reshaped leadership around national security and export-control oversight after Huang’s exit, emphasizing governance changes ahead of its next quarter and the continuing geopolitical scrutiny on advanced chips.
Anthropic priced its IPO at $83 per share ahead of its debut, while Nvidia heads toward a seventh straight weekly decline amid fresh US pressure on AI chip exports.
A single software issue highlighted weaknesses in payment-related systems, according to a report that described delays affecting Zelle transactions.
The crypto exchange is tied to a move to issue tokenized US stocks on the Base network, raising questions about how onchain share representations could expand access to traditional equities through 24/7 rails.
Goldman Sachs (NYSE:GS) is leading a $280 million round for Payhawk, aiming to expand the startup’s global Finance Operating System that connects payments and spend controls, according to a report citing the deal.
A report citing Cathie Wood’s ARK funds says they sold about $84.8 million of Nvidia shares before the company’s earnings period and used the cash to buy holdings tied to crypto markets.
The change reflects what Berkshire’s latest disclosure says happened to one of its long-running holdings after the company indicated an exit earlier in the year.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...